In a retrospective analysis published in 2019, of the 55 patients with HBV or HCV and advanced primary HCC who received anti-PD-1 agents (nivolumab and pembrolizumab), the median overall survival was 15 months, while the median progression-free survival (PFS) was 10 months. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.